Through experiments, Xu et al. further confirmed the expression of MAPK1 in ovarian carcinoma drug-resistant cells, providing evidence for the drug resistance mechanism and targeted therapy of tumors (33). This evidence concerns the gene MAPK1 and ovarian carcinoma.